One of the most studied probiotics in the world
BioGaia’s probiotic products with Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) are among the most scientifically well-documented probiotics in the world. To date the efficacy and safety of BioGaia’s different strains of L. reuteri have been documented in 224 clinical studies in around 18,000 people of all ages (May 2020).
BioGaia’s strains of L reuteri has been tested in 110 studies in children, from newborns up to 18 years old, and in 114 studies in adults.
Our probiotic strains with L. reuteri
L. reuteri Protectis (L. reuteri DSM 17938)
- For gut comfort
- 152 completed clinical trials in 14 800 individuals
L. reuteri Prodentis (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289)
- For gums and teeth
- 42 completed clinical trials in 2 065 individuals
L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
- For GI tract
- 8 clinical trials
L. reuteri Osfortis (L. reuteri ATCC PTA 6475)
- For bone health
- 1 clinical trial
L. reuteri Colus (L. reuteri ATCC PTA 4659)
- This product is still under development for colon health.
- 1 clinical trial
Why choose L. reuteri?
- L. reuteri is of human origin and one of few bacterial species that has co-evolved with humans since the beginning.
- Our L. reuteri products are of the highest quality and are manufactured under controlled conditions.
- Efficacy and safety are tested and documented in the target populations, from newborns to the elderly.
- Our probiotics contain viable freeze-dried L. reuteri.
- The number of live bacteria is guaranteed until expiry.
- The probiotic bacteria are always defined on strain level.
L. reuteri survive through the whole GI tract
Many probiotics die when they encounter the acidic environment of the stomach, but L. reuteri survive throughout the entire GI tract and beyond. Samples taken from throughout the body show that L. reuteri is present in:
- Breast milk
- The vagina
- The mouth
- The stomach
- The small intestine
- The large intestine
Where do our probiotic strains come from?
The first strain of L. reuteri for human use, L. reuteri DSM 17938, was isolated in 1990 from the breast milk of a Peruvian mother living in the Andes. Other human strains from BioGaia are L. reuteri ATCC PTA 5289, which is used in oral health products and was isolated from the oral cavity of a Japanese woman with remarkably good dental health. L. reuteri ATCC PTA 6475 is an anti-inflammatory strain isolated from the breast milk of a Finnish woman.
Today L. reuteri bacteria are produced in modern production facilities under controlled conditions to ensure that the product you buy contains exactly the same bacterial strain every time. The bacteria are cultured with the correct food and temperature to grow and duplicate. Through careful testing and quality control, each dose has the right number of viable organisms with no contaminants.
The right dose for colonisation
Even an indigenous bacterium like BioGaia’s L. reuteri Protectis should be taken on a regular basis to reach high enough levels to achieve proper colonisation and have a good effect.
Biopsies have shown that L. reuteri temporarily binds to the epithelial lining, which covers our GI tract and works like a skin on the inside of our bodies. The main task of this “inner skin” is to differentiate between what should be absorbed and what should not be let into our bodies.
The cells in our epithelial lining are replaced every fourth day, however, so the majority of L. reuteri cells are washed away within a week or so. Since L. reuteri colonisation is transient, daily intake is recommended to ensure adequate and stable levels of L. reuteri in the GI tract.
Clinical studies show that 100 million units per day is a safe and efficient dose of L. reuteri Protectis for children and adults. Each probiotic has a different recommended dose depending on which strain or strains the product contains.
Safe for all ages
Safety has been proven in babies, infants, children, healthy adults and immunocompromised adults. Even when taken at 10 billion units per day – meaning 1 000 times the recommended daily dose – no serious adverse effects have been observed.
L. reuteri throughout life
L. reuteri is a species of bacteria that is grounded in evolution. It lives in the GI tract of animals, with each species carrying its own specialised strains that are passed down through generations. Humans and their ancestors have co-evolved with their own strains of L. reuteri over millions of years.
As a result of this evolutionary process, L. reuteri contributes to human health throughout life. Humans are born almost sterile and first encounter L. reuteri during the birthing process and through breastfeeding. As a key member of the gut microbiota, L. reuteri plays an important role in helping babies to digest breast milk and solids foods. Throughout life, the bacteria tighten the lining of the gut to prevent leakage and improve immune response. They also release molecules that promote a healthy and diverse microbiota and prevent the growth of pathogens. Supporting the gut microbiota is especially important later in life, because elderly individuals tend to lose diversity in their guts.
Some people today still have L. reuteri as part of their microbiota, but many people lack these strains as a result of our modern lifestyles. A low-fibre diet, increased sanitation, antibiotic use and rising rates of birth by Cesarean section, which do not expose babies to the bacterium, have all played a role in depleting L. reuteri from our gastrointestinal (GI) tract.
People can reintroduce L. reuteri through the use of probiotics, but they must be replenished frequently, since the bacteria are continually washed out of the GI tract.
BioGaia's products with L. reuteri are sold through around 80 local distribution partners in 100 countries around the world.
BioGaia is an innovative Swedish health care company and a world leader in probiotics.
Probiotics grounded in evolution Driven by science
To date, 224 clinical studies using BioGaia’s human strains of L. reuteri have been performed on 18,000 individuals of all ages (May 2020).